Sumitomo Mitsui Trust Group Inc. Grows Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 314,452 shares of the biopharmaceutical company’s stock after acquiring an additional 20,910 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned approximately 0.24% of Alnylam Pharmaceuticals worth $143,390,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. First Horizon Corp purchased a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $62,000. MGO One Seven LLC acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at $319,000. Covenant Partners LLC purchased a new position in Alnylam Pharmaceuticals during the third quarter worth $275,000. ORG Partners LLC raised its holdings in shares of Alnylam Pharmaceuticals by 70.2% in the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 33 shares during the last quarter. Finally, MASTERINVEST Kapitalanlage GmbH purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at $225,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $370.91 on Tuesday. The company has a market cap of $49.00 billion, a P/E ratio of 1,545.46 and a beta of 0.32. The firm’s 50 day moving average is $424.46 and its two-hundred day moving average is $421.61. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 15,650 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $453.69, for a total value of $7,100,248.50. Following the transaction, the chief executive officer directly owned 65,409 shares in the company, valued at $29,675,409.21. This trade represents a 19.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 12,128 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $452.18, for a total value of $5,484,039.04. Following the completion of the transaction, the executive vice president directly owned 21,264 shares in the company, valued at $9,615,155.52. This represents a 36.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 37,778 shares of company stock worth $17,096,988 over the last ninety days. Corporate insiders own 1.20% of the company’s stock.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam launched its five‑year “Alnylam 2030” strategy to scale operations, emphasize TTR leadership and expand the pipeline — a constructive road map for long‑term growth and revenue scaling. Alnylam Launches “Alnylam 2030” Strategy
• Positive Sentiment: Needham raised its price target to $529 (buy), signaling confidence in Alnylam’s medium‑term upside and supporting a constructive analyst view. Alnylam Lays Out 2030 Vision, Bets On TTR Leadership And Pipeline Scale
• Neutral Sentiment: Bank of America adjusted its target slightly (from $530 to $529) but kept a buy rating — little change to the fundamental analyst stance. Bank of America Price Target Update
• Neutral Sentiment: Alnylam presented at the 44th Annual J.P. Morgan Healthcare Conference; the transcript provides management’s messaging on product performance, pipeline priorities and the 2030 plan — useful for investors parsing guidance and execution risk. Alnylam Presents at JPM Transcript
• Neutral Sentiment: Sector coverage at JPM and industry pieces (e.g., AbbVie/PD‑1 VEGF competition, market forecasts) set context for Alnylam’s competitive positioning but don’t change company‑specific fundamentals immediately. AbbVie Buys into PD‑1/VEGF Sweepstakes
• Negative Sentiment: Short interest rose materially in late December to ~5.53M shares (≈4.2% of float) — a 32.2% increase from mid‑December — which can add selling pressure and amplify downside on weak days (short‑interest ratio ≈2.9 days). This elevated short positioning likely contributed to today’s pullback.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Raymond James Financial reiterated an “outperform” rating and set a $472.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday. Barclays lifted their price target on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, November 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Needham & Company LLC increased their price target on Alnylam Pharmaceuticals from $520.00 to $529.00 and gave the stock a “buy” rating in a research note on Monday. Twenty-two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $490.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.